Cancer type/
the study number
CapeOX /TCOG GI-1601
Kawabata R. Gastric Cancer.2022 phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancert: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study
Okuma Y. Future Oncol. 2022 Feb;18(5):523-531.
 doi: 10.2217/fon-2021-0892. Epub 2022 Jan 17.
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protokol pf phase 2 study (UNICORN/TCOG1901)
CapeOX /TCOG GI-1601
Chin K. Anticancer Res
. 2022 May;42(5):2683-2687.
 doi: 10.21873/anticanres.15746.
Initial Safety Analysis of CapeOx for Elderly Patients With
Advanced Gastric Cancer Patients: A Phase II Trial
Denda T. Eur J Cancer.2021;154:296-306.Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX+Bev as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-laber, phase III, non-inferiority trial.
Takahashi S. Cancer Science. 2021;112:1567-1578.Advanced colorectal cancer subtypes(aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
TCOG GI-1301
Yamano T. Nutrition. 2020 Sep;77:110807. doi: 10.1016/j.nut.2020.110807.Influence of chemotherapy on nutritional status in locally advanced rectal cancer: Prospective multicenter study.
TCOG 1101
Kasai T. Int J Clin Oncol. 2020; 25:867–875. doi:10.1007/s10147-020-01629-6.A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101-
Nishikawa K. Gastric Cancer. 2020 Jan;23(1):160-167. doi: 10.1007/s10120-019-00990-4.Meta‑analysis of two randomized phase III trials (TCOG GI‑0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin
versus irinotecan alone as second‑line treatment for advanced gastric cancer
TCOG LC-1202
Miyanaga A. Jpn J Clin Oncol
. 2019 Aug 1;49(8):749-754. doi: 10.1093/jjco/hyz064.
Phase II traial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC1202)
Yamada Y. Ann Oncol. 2018 Mar 1;29(3):624-631.
 doi: 10.1093/annonc/mdx816.
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized , open-label, phase III, noninfeority trial
TCOG GI-0802
Sato T. Radiother Oncol. 2016 Aug;120(2):222-7.
 doi: 10.1016/j.radonc.2016.06.002.
A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)
Aotani E. Int J Clin Oncol
. 2016 Oct;21(5):836-842. doi: 10.1007/s10147-016-0960-6.
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Komatsu Y. BMC Cancer. 2015 Sep 9;15:626. doi: 10.1186/s12885-015-1630-1.Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
Kubota K. Ann Oncol
. 2015 Jul;26(7):1401-8. doi: 10.1093/annonc/mdv190.
A randomized phase Ⅲ trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advances non-small-cell lung cancer: TCOG0701 CATS Trial
Nakayama N. Invest New Drugs. 2015 Aug;33(4):954-62. doi: 10.1007/s10637-015-0239-1.A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study
S.Sugawara Ann Oncol
. 2015 May;26(5):888-894. doi: 10.1093/annonc/mdv063.
Randomized Phase II Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-small Cell Lung Cancer with Sensitive EGFR Mutations: NEJ005/TCOG0902
Kawano Y. (TCOG代表としてTakiguchi Y.)Respir Investig
. 2014 Nov;52(6):339-47. doi: 10.1016/j.resinv.2014.06.004.
Current status and future perspectives of cooperative study groups for lung cancer in Japan
Takiguchi Y. Int J Clin Oncol
. 2015 Aug;20(4):659-67. doi: 10.1007/s10147-014-0755-6.
Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer
Matsumoto Y. Lung Cancer
. 2014 Nov;86(2):195-200. doi: 10.1016/j.lungcan.2014.08.019. Epub 2014 Sep 16.
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903)
Higuchi K. Eur J Cancer
. 2014 May;50(8):1437-45. doi: 10.1016/j.ejca.2014.01.020. Epub 2014 Feb 20.
Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase Ⅲ trial (TCOG GI-0801/BIRIP Trial)
弦間昭彦. 日本内科学会雑誌. 2013;102:1248-1251. 非小細胞肺癌に対するCDDP and TS-1(CATS) trial
非小細胞肺癌Takiguchi Y. Lung Cancer
. 2010 Jun;68(3):409-14. doi: 10.1016/j.lungcan.2009.08.009.
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small sell lung cancer
Koizumi W. Jpn J Clin Oncol
. 2009 Nov;39(11):713-9. doi: 10.1093/jjco/hyp099.
Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer A Report from the Gastrointestinal Oncology Group of The Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial
高齢者進行胃癌Koizumi W. Cancer Chemother Pharmacol
. 2010 May;65(6):1093-9. doi: 10.1007/s00280-009-1114-6.
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study
Katakami N. J Thorac Oncol
. 2006 Jun;1(5):447-53.
Docetaxel in combination with either cisplatin(DC) or gemcitabine(DG) in unressctable non-small cell lung carcinoma(NSCLC):a randomaized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group
非小細胞肺癌Ichinose Y. Clin Cancer Res
. 2004 Dec 1;10(23):7860-4. doi: 10.1158/1078-0432.CCR-04-1200.
S-1 Plus Cisplatin Combination Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer:A Multi-Institutional Phase II Trial
非小細胞肺癌Kubota K. J Clin Oncol
. 2004 Jan 15;22(2):254-61. doi: 10.1200/JCO.2004.06.114.
Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer
進行胃癌Koizumi W. Anticancer Res
. Jul-Aug 2004;24(4):2465-70.
Randomized Phase Two Study Comparing Mitomycin,Cisplatin Plus Doxifluridine with Cisplatin Plus Doxifluridine in Advanced Unressectable Gastric Cancer
進行・再発胃癌二村浩史. 癌と化学療法 2003; 30(9):1289.切除不能・再発胃癌に対するTS-1とLentinanの併用療法
-Pilot Study-
固形癌忽滑谷直孝. 癌と化学療法 1995; 22(12):1821.癌化学療法におけるGranisetron単独療法とステロイド併用療法との比較検討
各種固形癌高橋秀夫. 癌と化学療法 1990; 17(10):2043.共同研究によるUFT E顆粒の臨床成績
消化器癌中津喬義. 癌と化学療法 1987; 14:3114.共同研究による新抗癌剤590-S(1-phthalidy-5-fluorouracil)の消化癌に対する第Ⅱ相臨床試験
固形癌二ツ木浩一. 癌と化学療法 1987; 14:1274.共同研究によるUFT細粒の臨床成績
進行固形癌佐藤博. 癌と化学療法 1986; 13(9):2807.固形がんに対するBH-AC併用療法の臨床的効果の検討(比較試験研究)
悪性腫瘍渡辺裕. 癌と化学療法 1980; 7:1588.共同研究によるUFT経口投与の臨床成績
各種進行癌石井好明. 癌と化学療法 1978; 5(6):87.共同研究によるACNUおよびピシバニール併用の臨床治験
各種進行癌小黒昌夫. 癌と化学療法 1977; 4(6):203.投与法別によるアドリアマイシンの悪性腫瘍に対する効果と副作用
各種進行癌古川喜一郎. 癌と化学療法 1976; 3(5):193.共同研究によるフトラフール坐剤の臨床成績
各種進行癌高橋 秀夫. 癌と化学療法 1976; 3(1):80.共同研究によるエスキノンの臨床治験
各種進行癌栗原稔. 癌と化学療法 1975; 2(3):75.共同研究によるMitomycin C,Dextran Sulfate,Urokinase併用療法の臨床試験
各種進行癌中津喬義. 癌と化学療法 1975; 2(1):131.共同研究による5-FU Dry Syrup経口投与の臨床成績
各種腺癌渡辺裕. 癌と化学療法 1974; 1(1):111.共同研究によるFT-207経口投与の臨床成績